# Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Source: https://onco.cc/trials/nct05978284/  
OnCo record `nct05978284` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ZG006 in small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.

## Summary

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma is a phase 1/2 interventional study registered as NCT05978284 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 54 participants planned, started 2023-10-27 and due to reach its primary completion in 2026-09. Interventions recorded: ZG006. Conditions listed: Small Cell Lung Cancer, Neuroendocrine Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05978284
- Phase: 1/2
- Setting: A Phase 1/2 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
- Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT05978284: https://clinicaltrials.gov/study/NCT05978284

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [ZG006](https://onco.cc/drugs/zg006/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct05978284.json